$ZVSA is anticipated to benefit from $VTYX's inflammasome event today. $VTYX saw upgrades from Oppenheimer and Wells Fargo to 'Outperform' and 'Overweight' with a $16 price target, leading to increased investor interest.
Lol Kinda late. $VTYX https://t.co/O7Dq984SI8
$VTYX upgraded to Overweight at Wells Fargo and Oppenheimer.
Last night , post close we had Oppenheimer upgrade $VTYX to an Outperform. Today, Wells Fargo is out upgrading $VTYX to Overweight with a $16 PT https://t.co/eTRzVTjTzE
$VTYX?
$ZVSA ready to ride coattails of $VTYX inflammasome event today. Disclosure: long, but with lots of questions about their science. Eg. how does their antibody reach cytoplasmic target...but guess this won't matter much for likely volatility :) https://t.co/PV5rVhY9s2